AIxplorerBio Entered A Broad Collaboration with Baidu’s PaddleHelix to Expedite the Construction of Its AI Small Molecule Drug R&D Platform
Time: 2022-05-18
Source: Viva Biotech
[Abstract]:The collaboration integrates the strengths of both companies in the fields of molecular generation and evaluation of druggability to jointly promote a new system of drug research and development based on AI technology.


On May 18, AIxplorerBio, a Viva BioInnovator portfolio company, announced a broad collaboration with PaddleHelix. The two parties will leverage their strengths and collaborate in the fields of de novo molecular design and druggability evaluation, to accelerate new AI-powered drug research and development platform. The collaboration takes fully advantage of PaddleHelix's strengths in AI technologies and AIxplorerBio's experience in new drug R&D and experiemental capabilities to jointly develop AI-powered drug discovery models. Dr. David. Xu, CEO of AIxplorerBio, emphasized, "AIxplorerBio is an AI-powered, structure-based drug R&D biotech company. The collaboration with Baidu's PaddleHelix will help enhance our new AI drug R&D platform - AIxMolTM, and speed up the development of our pipeline.

About AIxplorerBio


We are an AI-powered, structure-based drug R&D biotech company. We focus on the discovery and development of new medicines for immunological and neurodegenerative diseases. In the quest for the new medications, we are committed to creating a AI-powered, data-driven, structure-based, efficient drug R&D paradigm through introduction, cooperation and technological innovation.


AIxplorerBio is established by a team of highly experienced new drug R&D experts and sponsored by the new B/IT (biotechnology and information technology) powerhouse, BioMap, and the leading drug discovery CRO platform, Viva Biotech. In addition to the strategic cooperation with BioMap and Viva, AIxplorerBio also actively seeks collaboration opportunities with AI-oriented technology companies as well as drug R&D companies to explore more efficient new drug R&D paradigm.

Media contact:
Contact Us